ATE264691T1 - Newcastle-krankheitsvirus-kombinationsimpfstoff - Google Patents

Newcastle-krankheitsvirus-kombinationsimpfstoff

Info

Publication number
ATE264691T1
ATE264691T1 AT96202866T AT96202866T ATE264691T1 AT E264691 T1 ATE264691 T1 AT E264691T1 AT 96202866 T AT96202866 T AT 96202866T AT 96202866 T AT96202866 T AT 96202866T AT E264691 T1 ATE264691 T1 AT E264691T1
Authority
AT
Austria
Prior art keywords
combination vaccine
disease virus
newcastle disease
virus combination
vaccine
Prior art date
Application number
AT96202866T
Other languages
English (en)
Inventor
Carla Christina Schrier
Heinrich Dieter Luetticken
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE264691T1 publication Critical patent/ATE264691T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96202866T 1995-10-18 1996-10-15 Newcastle-krankheitsvirus-kombinationsimpfstoff ATE264691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202810 1995-10-18

Publications (1)

Publication Number Publication Date
ATE264691T1 true ATE264691T1 (de) 2004-05-15

Family

ID=8220728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96202866T ATE264691T1 (de) 1995-10-18 1996-10-15 Newcastle-krankheitsvirus-kombinationsimpfstoff

Country Status (11)

Country Link
US (1) US5733556A (de)
EP (1) EP0770397B1 (de)
JP (1) JP3947254B2 (de)
AT (1) ATE264691T1 (de)
BR (1) BR9605153B1 (de)
CA (1) CA2187974C (de)
DE (1) DE69632235T2 (de)
DK (1) DK0770397T3 (de)
ES (1) ES2219679T3 (de)
MX (1) MX9604907A (de)
PT (1) PT770397E (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
CA2312626A1 (en) * 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
CA2431938A1 (en) * 2001-02-15 2002-10-10 The Registrar, Indian Institute Of Science A novel vaccine formulation consisting of dna vaccine inactivated virus
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US20040146530A1 (en) * 2002-01-30 2004-07-29 Sharma Jagdev M Avian vaccine effective against infectious bursal disease virus
US20040057969A1 (en) * 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
CA2500661A1 (en) * 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
CN100393870C (zh) * 2003-05-05 2008-06-11 波依斯汤普森植物研究所 用于制备免疫保护性组合物的载体和来源于转基因植物的细胞
RU2259844C1 (ru) * 2004-01-22 2005-09-10 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) Вирус-вакцина против ньюкаслской болезни птиц
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
EP2813144A1 (de) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgetische Zusammensetzungen enthaltend ein Antihistamin
KR20100047860A (ko) * 2007-07-06 2010-05-10 누온 테라피우틱스, 아이엔씨. 신경병증 통증의 치료
RU2347584C1 (ru) * 2007-11-22 2009-02-27 Федеральное государственное учреждение "Всероссийский государственный центр качества и стандартизации лекарственных средств для животных и кормов" (ФГУ "ВГНКИ") Вакцина против ньюкаслской болезни
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
EP3090743A1 (de) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
RU2403060C2 (ru) * 2008-03-04 2010-11-10 Владимир Олегович Виноходов Способ профилактики болезни ньюкасла
EP2379504A2 (de) 2008-12-22 2011-10-26 Sloan Kettering Institute For Cancer Research Verbindungen auf coumarinbasis
US9056857B2 (en) 2008-12-22 2015-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
CA2752800C (en) 2009-02-24 2017-12-05 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011042482A1 (en) 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
KR101099629B1 (ko) 2009-10-27 2011-12-29 건국대학교 산학협력단 신규한 뉴캣슬병 바이러스 ｋ148/08주, 및 그 바이러스를 함유하는 뉴캣슬병 백신
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
EP2563372A4 (de) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc Präbiotische formulierungen und verwendungsverfahren dafür
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP2576520A1 (de) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radioaktiv markierte verbindungen und ihre verfahren
EP4014989A1 (de) * 2010-08-31 2022-06-22 Boehringer Ingelheim Animal Health USA Inc. Auf das virus der newcastle-krankheit gerichtete herpesvirus-impfstoffe
ES2646835T3 (es) 2010-10-18 2017-12-18 Cerenis Therapeutics Holding Sa Compuestos, composiciones y procedimientos útiles para la movilización del colesterol
EP2704740B1 (de) 2011-05-04 2016-10-05 Streck, Inc. Inaktiviertes schweinegrippe-virus und verfahren zu seiner herstellung
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
JP2015514712A (ja) 2012-03-27 2015-05-21 インクロン エルエルシー 乳癌治療に使用されるｃｕｒａｘｉｎおよび奏効の可能性のある患者の識別方法
EP2844250B1 (de) 2012-05-01 2017-11-08 Translatum Medicus Inc. Verfahren zur behandlung und diagnose von erblindenden augenerkrankungen
WO2014077096A1 (ja) * 2012-11-15 2014-05-22 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
ES2967976T3 (es) 2014-05-19 2024-05-06 Univ Northeastern Compuestos dirigidos a receptor de serotonina
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
US10183060B2 (en) 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
EP3371311B1 (de) 2015-11-06 2021-07-21 Orionis Biosciences BV Bifunktionale chimäre proteine und verwendungen davon
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
EP3423041A4 (de) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
JP7657014B2 (ja) 2016-03-07 2025-04-04 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3052523A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
EP3580230A1 (de) 2017-02-07 2019-12-18 VIB vzw Auf immunzellen gerichtete bispezifische chimäre proteine und verwendungen davon
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
RO132299A3 (ro) 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
AU2019215440B2 (en) 2018-02-05 2025-12-04 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2020047328A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
JP2022519779A (ja) 2019-02-07 2022-03-24 アルサテック，インコーポレイテッド エモキシピンの多価誘導体
EP3986163A2 (de) 2019-06-19 2022-04-27 Solarea Bio, Inc. Mikrobielle zusammensetzungen und verfahren zur herstellung von aufgewerteten probiotischen zusammenstellungen
AU2020347180A1 (en) * 2019-09-11 2022-03-24 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
CN111334464B (zh) * 2020-03-30 2023-05-12 重庆市畜牧科学院 鹅副粘病毒在加快鹅成纤维细胞增殖速度中的应用
CN114164182B (zh) * 2020-09-10 2024-02-06 青岛易邦生物工程有限公司 一种基因vii型遗传拯救的新城疫病毒疫苗株
CN113376387B (zh) * 2021-07-13 2023-03-24 中崇信诺生物科技泰州有限公司 一种鸽新城疫Ⅵb亚型阳性血清标准品及其制备方法
WO2023034507A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
EP4396330A1 (de) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Verfahren und zusammensetzungen zur induktion von fötalem hämoglobin
US20230083717A1 (en) 2021-09-01 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for promoting adipocyte beiging
EP4396331A1 (de) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Verfahren und zusammensetzungen zur induktion von fötalem hämoglobin, modulation erythroider zellinien und störung von megakaryozytenlinien
WO2023039164A2 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023039162A1 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating enteroendocrine cells
WO2023043827A2 (en) 2021-09-14 2023-03-23 Flagship Pioneering Innovations Vi, Llc Methods and compositions for perturbing monocyte and neutrophil lineages
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
DE68918649T2 (de) * 1988-07-18 1995-03-23 Duphar Int Res Lebende Newcastle-Krankheit-Virus-Vakzine.
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof
HU203983B (en) * 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
US5118502A (en) * 1989-06-20 1992-06-02 The University Of Georgia Research Foundation, Inc. Naturally attenuated newcastle disease vaccine and method of using the same
EP0696204A4 (de) * 1993-02-26 1999-03-31 Syntro Corp Rekombinierter geflügelpockenvirus und seine verwendung
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal

Also Published As

Publication number Publication date
CA2187974C (en) 2006-08-29
CA2187974A1 (en) 1997-04-19
BR9605153A (pt) 1998-07-14
EP0770397A1 (de) 1997-05-02
BR9605153B1 (pt) 2010-07-27
PT770397E (pt) 2004-08-31
ES2219679T3 (es) 2004-12-01
MX9604907A (es) 1997-04-30
DE69632235T2 (de) 2004-08-26
DE69632235D1 (de) 2004-05-27
JP3947254B2 (ja) 2007-07-18
US5733556A (en) 1998-03-31
JPH09169663A (ja) 1997-06-30
EP0770397B1 (de) 2004-04-21
DK0770397T3 (da) 2004-08-09

Similar Documents

Publication Publication Date Title
ATE264691T1 (de) Newcastle-krankheitsvirus-kombinationsimpfstoff
DE69016956D1 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
ATE229978T1 (de) Helicobacter proteine und impstoffe
PT1403375E (pt) Vacina viva recombinante aviária, utilizando como vector um vírus de herpes aviário
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
HUP9800946A2 (hu) Készítmény citotoxikus T-limfocita válasz kiváltására
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BR9710012B1 (pt) vacina veterinária viva recombinante e fórmula de vacina multivalente.
ES2152292T3 (es) Vacuna para aves de corral que contiene el virus de la bronquitis infecciosa 4/91.
FI955101A7 (fi) Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten
ZA975618B (en) Avian recombinant live vaccine using as vector the avian infectious laryngotrachetis virus
AU7814498A (en) Multivalent (in ovo) avian vaccine
ID24174A (id) Vector dari porcine adenovirus
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
DK0838222T3 (da) Vaccinesammensætninger, der omfatter inaktiverede immunogener og levende kyllingeanæmi-virus (CAV)
HUP9901958A2 (hu) Sertés reproduktív és respirációs szindróma vakcina
DE69531793D1 (de) Immunogene zubereitungen
ATE334697T1 (de) Boviner atmungs- und darmcoronavirus als impfstoff
DK0547102T3 (da) Opløseliggørelse af proteiner på aktiv form
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
NZ228232A (en) Live combined vaccine comprising at least one live infectious bronchitis virus and at least one other virus infectious to poultry
DK0729509T3 (da) Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme
AR007611A1 (es) Linea celular de pollo infectada con virus de la enfermedad de marek perdurable, metodo para producir la linea celular, vacuna para aves y lineacelular de herpesvirus de la enfermedad de marek

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0770397

Country of ref document: EP